<DOC>
	<DOC>NCT01280721</DOC>
	<brief_summary>ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).</brief_summary>
	<brief_title>A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients who participated in Trial 15604251 in Japan and for whom CRF collection has been completed. Patients who completed 3year repeated administration and who completed the second followup visit or patients whose treatment with the trial drug was interupted due to pregnancy and who completed out the second followup visit in Trial 15604251. Patients in whom any adverse events occurring in Trial 15604251 were resolved orstabilized and require no further followup. Patients with eGFR of less than 15 mL/min/1.73 m2 Pregnant, breastfeeding, or possibly pregnant women or women who are planning to become pregnant Patients who received any investigational drug other than Tolvaptan within 30 days prior to commencement of administration of tolvaptan Any patients who, in the opinion of the principle investigator or subinvestigators, should not participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>53 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>